MedTrace Logo

Immune Checkpoint Inhibitor Therapy- Induced Endocrinopathy

NCT04079647 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-09-06

No results posted yet for this study

Summary

To review cases from NTUH who developed endocrinopathy and metabolic diseases after immunotherapy, and statistically analyzed their age, clinical presentation, image findings, treatment and its response.

Conditions

  • Endocrinopathy

Interventions

DRUG

Immunotherapy

Patients receive immunotherapy for cancer treatment

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Shyang-Rong Shih, MD, PhD · National Taiwan University Hospital

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-03
Primary Completion
2025-07-01
Completion
2025-07-01

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04079647 on ClinicalTrials.gov